Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

J. Hyánek, R. Matalon, P. Rady, S. Szucs, P. Šebesta, J. Matoušková, H. Pejznochová, L. Dubská, H. Přindisová, J. Dvořáková, M. Loučka, V. Martiníková, M. Slancová

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

Original languageEnglish (US)
Pages (from-to)72-76
Number of pages5
JournalKlinicka Biochemie a Metabolismus
Volume10
Issue number2
StatePublished - Jan 1 2002
Externally publishedYes

Keywords

  • Cobalamin
  • Folate
  • Mild hyperhomocysteinaemia vitamin supplementation
  • Polymorphism of MTHFR and MTRR
  • Pyridoxal phosphate

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases'. Together they form a unique fingerprint.

Cite this